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FEATURE

THE LOWDOWN ON

OUT-OF-COMPETITION
TESTING

WHAT THE RMTC ISN’T TELLING US ABOUT ITS PROPOSED REGULATIONS
By Clara Fenger, DVM, PhD, DACVIM; Tanya Boulmetis, JD; Kim Brewer, DVM; and Thomas Tobin, MRCVS, Phd, DABT; Photos by Denis Blake

T

he corner office has a beautiful view, with filtered sunlight shining
through full plate glass. Grand old oak trees provide shade for much
of the year to the building that houses the registry of the American
Thoroughbred. Professionals. Many years of experience populate
the offices, far from the distinctive scent and dust of the racetrack. Among
those distinguished leaders are men who began their careers working up from
the mailroom of a racetrack or from the stables of an Arabian horse farm.
Many years and miles removed from the actual day-to-day work of sending
out a Thoroughbred for a morning workout, mucking stalls or rubbing down

the athlete at the end of the morning, these executives propose to reform
medication rules. Their latest initiative to this end is support of an out-ofcompetition testing regulation promulgated by the Racing Medication and
Testing Consortium (RMTC), an organization housed under the same roof,
shaded by the same oak trees.
Horse racing is both the Sport of Kings and an economic engine for people
across all spectra of socioeconomic status. The reliance on wagering to sustain
the sport leads many to suspect that anyone who wins at a high percentage
must be using “something” to gain an unfair advantage over his or her
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competitors. The perceived potential for such activities has led to a unique and
early history of drug testing advances in horse racing, with methods that long
predate drug testing in any human sport. This attention to the integrity of the
sport has paid off for modern-day horse racing, with fewer than 0.5 percent of
all post-race tests returning a positive, and most of those are trace overages of
therapeutic medications that would be legal, indeed at times not even tested
for, in any human sport. This low violation rate is less than half of the number
of violations reported in human sports, and it does not include the widespread
practice of approved therapeutic use exemptions in human drug testing,
in which otherwise prohibited drugs are permitted during competition for
therapeutic use. The only area in which human testing has surpassed equine
testing is in its common use of out-of-competition testing.

ERYTHROPOIETIN

Out-of-competition testing is important because some substances
can exert an effect on an athlete long after the substance can no longer be
detected in the typical post-race drug-testing sample. The poster-child drug
for which out-of-competition testing is required is erythropoietin (EPO) and its
analogues. EPO is a hormone produced by the kidneys in response to a reduced
oxygen environment; it travels from the kidneys to the bone marrow, where it
stimulates the production of red blood cells. This hormone is naturally present
all the time in all horses, and the balance of EPO, iron and key vitamins folate
and B12 combine to maintain a steady level of red blood cell production by the
bone marrow.
This balance is important in maintaining the delivery of oxygen to
exercising muscles—a key determinant of optimal racing performance. Horses
are unique among athletes in that their blood moves with such great speed
throughout their bodies and across their lungs during maximal effort that
the blood cannot be fully saturated with oxygen as it traverses the pulmonary
circulation. This exercise-associated hypoxemia is not observed in other
species and likely contributes to the possibility of improvement in performance
following EPO administration in horses. If you can increase the oxygen-carrying
capacity of the blood, you can deliver more oxygen to the muscles.

The Jockey Club-supported RMTC regulation would ban some
theraputic medications at any time during the competition life
of the horse—on the backside of a racetrack, on farms, even
at layup facilities in states in which no racing is held.
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What makes EPO a hormone of great threat to the integrity of any sport
is that small doses administered at regular intervals will stimulate the
production of red blood cells, cells that persist in the bloodstream for months
and far outlast the two- to three-day presence of detectable amounts of the
EPO hormone in blood. In this way, any performance-enhancing effect of EPO
would long outlive the ability of any testing laboratory to actually detect the
offending EPO.

OUT-OF-COMPETITION
TESTING

In 2007 the Association of Racing Commissioners International (RCI)
adopted an out-of-competition testing regulation, which, for the first time,
instituted a policy for the collection of blood samples for the detection of
EPO outside of the post-race testing situation. This regulation represented
a significant advance in the ability of racing commissions to address the
problem of EPO misuse in horse racing. Since that time, out-of-competition
testing has steadily increased, with a high of 3,805 such tests in 2015, of
which 45 returned a laboratory finding (a 1.2 percent positive rate). None of
those positives actually represented an illegal finding. Cobalt was responsible
for 44 of those findings, which did not even represent an illegal finding at
the time of the testing and could have resulted from the sampling of a horse
shortly after an innocent administration of vitamin B12. The remaining finding
was for the dewormer levamisole, a substance of invaluable use in horses as
an immune modulator for such diseases as equine protozoal myelitis or Lyme
disease. So the 1.2 percent positive rate from 2015 represented not a single
real violation. Either racing is doing a great job in controlling illicit substance
administrations or we are not testing a sufficient number of horses.
In a recent statement published in Thoroughbred Daily News, The Jockey
Club President and COO Jim Gagliano challenged the racing industry to adopt
the RMTC’s far-reaching out-of-competition testing proposal to ensure “the
integrity of competition.”
Surely, if out-of-competition testing could be expanded, we as an industry
could confidently proclaim that all is being done to ensure the integrity of horse

racing. As outlined above, EPO poses a substantial threat to the integrity of
horse racing, and every stakeholder in the industry should stand firmly behind
the expansion of out-of-competition testing. Or should they? First, let’s look
carefully at the actual RMTC proposal.

THE RMTC PROPOSAL

The RMTC’s proposal would expand out-of-competition testing well
beyond EPO and related agents and directly into routine practice of veterinary
medicine. First, it bans all non-FDA-approved substances, an apparently
noble goal on its surface; after all, drug companies have expended millions
to demonstrate that their FDA-approved drugs are safe and effective, and our
industry should be in support of making sure that our athletes receive only
the highest-quality medicines. The first exception is that our federal and state
governments have made numerous provisions for the use of medications that
were in widespread use at the time that the current system of FDA approval
was introduced, as well as for the use of compounded medications, which are
legal when there is no FDA-approved alternative available. Strict restrictions
are already in place for the control of such substances in post-race testing, but
The Jockey Club-supported RMTC regulation would ban them at any time during
the competition life of the horse—on the backside of a racetrack, on farms,
even at layup facilities in states in which no racing is held. Aside from the
negative impact on the athlete itself, when treatment options for any number
of conditions would be limited, trainers and owners could be held liable for the
actions of any manager or veterinarian, unlicensed by any commission, acting
innocently and in good faith in the best interests of the health and welfare of
the horse.
The list of prohibited substances appears to have been slightly modified
from the list that appears on the World Anti-Doping Agency website
(wada-ama.org/en/what-we-do/prohibited-list) and includes cytokines and
growth factors, which are specifically used in regenerative medicine, such as
Interleukin-1 Receptor Antagonist Protein and platelet-rich plasma, for which,
incidentally, no detection technology, out-of-competition testing or otherwise,
currently exists. In human sports, such methods of promoting better and faster
healing from sports injuries are considered illegal, taking an unfair advantage
over competitors. This concept of “cheating” is inappropriate in equine sports,
where failing to allow a horse to recuperate to its fullest extent could both
predispose the horse and its rider to catastrophic injury and prevent the
equine athlete from having a successful second career after racing. The use
of such growth factors as targeted therapies for joints, tendons and ligaments
should be encouraged in our athletes rather than added to a long list of
prohibited substances.
Thyroxine, adrenocorticotropin and human chorionic gonadotropin,
substances in common use for the purpose of treating specific conditions
in horses, are included on the RMTC’s proposed rule. The RMTC provides no
evidence that the use of any of these substances poses a risk to the integrity
of racing. These substances are currently prescribed pursuant to a specific
diagnosis in horses both on and off the track on a daily basis. This regulation
seeks to permit the use of thyroxine only after permission is given by the
regulatory authority. So if your vet pulls a blood test and determines that
the horse has a low level of thyroxine, you cannot supplement the horse until
permission is received by the regulatory authority. The RMTC’s regulation would
put bureaucrats in the place of your own veterinarian in making health and
welfare decisions for your horse.
There are many issues with this scenario of regulatory permission
being required to use a legal medication during training or recuperation. For
example, say the state that you requested permission from refuses to allow
the medication. After the refusal, you ship to another state, again request

permission, have it granted and medicate your horse. Then the state that
refused permission tests your horse out of competition. Obviously, it would
be positive. Who is liable? State budgets are constrained enough without
looking for lawsuits. Another issue would be the timeframe between requesting
permission and receiving it. It would put the commission in the untenable
position of being able to refuse or delay approval in order to tacitly punish a
horseman who, without any proof, they “felt” was cheating.
Anabolic steroids would be further restricted in this out-of-competition
testing regulation well beyond their current restrictions within proximity
to racing. Horses are unique among athletes in that we geld our athletes,
for which there is no corollary in human sports. Anabolic steroids may be
required for normal recovery from injury and disease, and like growth factors,
any intervention we can provide to horses that may lead to a fuller and more
rapid recovery should be encouraged. Any human bodybuilder or weight lifter
can attest that using cycles of anabolic steroids will enhance performance,
but the existing minimum withdrawal of 60 days from racing prevents such
abuse. This regulation would require placing the horse on the vet’s list for six
months, which is lightyears in horse racing, and would effectively ban the use
of these substances at any time in a racing horse. Further, stanozolol, the only
FDA-approved anabolic steroid that provides the benefits of anabolic steroids
without the disadvantage of causing studdish behavior, would be banned at
all times. This regulation would prevent the beneficial use of anabolic steroids
based solely on the premise that it looks good to the public.

THERAPEUTIC SUBSTANCES

In addition to the restrictions on specific widely used therapeutic
substances, an even more sinister provision is hidden within this proposed
regulation. A provision calls for out-of-competition testing to be used to police
other racing regulations not contained within the language of the out-ofcompetition testing regulation. On the surface, this sounds innocuous enough,
but a careful review reveals the following possible intent in the regulation. If a
horse tests positive for a therapeutic substance—for example, methocarbamol
or dexamethasone—and there is no vet record or prescription for that
substance for that horse, a violation has occurred. In the current environment
of picogram identifications at the laboratory, where most methocarbamol and
dexamethasone identifications are the result of inadvertent environmental
contamination, trainers will be penalized for trace medication levels over which
they have no control.
A further issue with this scenario would be for a medication of which
trace levels may be found for an extended period of time after the last
administration. For example, horses in training can be purchased at auction,
leading to the question of who is liable when a horse that recently has been
purchased tests positive and only has been in its new barn for a few weeks.
New York takes this into account and has a provision through which the new
owner may void the purchase within 10 days of notification. However, what if
the sale was months ago? The conditions of sale for both Keeneland and FasigTipton do not take a position through which a horse may be returned months
later. Again, this could be an expensive litigation scenario for both states and
horsemen. There is even a provision in the proposed RMTC regulation for hair
testing, in which substances could be found for up to a year later, and other
biologic samples as yet undefined.

EXISTING REGULATIONS

A racing commission that is considering adopting the RMTC’s
recommendation should carefully evaluate the validity of the out-of-competition
testing rules; they need to consider whether it falls within the scope of the
WWW.NATIONALHBPA.COM
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jurisdiction conferred by their legislature. Each state has its own enabling
statute concerning horse racing. In general, the proposed rule must have a
rational and reasonable basis and be based on objective science. It must
safeguard the constitutional rights and ensure fairness to all horsemen. In
2006 Ontario was the first jurisdiction to launch an out-of-competition testing
program, and many jurisdictions followed suit. These adopted rules range from
the very narrow, in which there are defined parameters of which horses are
eligible and what is tested for, to extremely broad, in which a state could make
a case to test the majority of the horse population in the United States—even
if that horse had never been in that specific state.
Some states test only for the blood doping substances and limit the
eligible horses to jurisdiction grounds or to horses that are racing in the
state. Some test only blood, and others allow urine and hair testing. Other
states, however, are testing for a very broad range of substances, some
of which include drugs that can be a result of inadvertent environmental
contaminations, such as zilpaterol and ractopamine.
Delaware falls into the narrow out-of-competition testing rule category.
The state tests for blood doping on any entered horse, any horse that raced
there within the past 60 days, any horse that showed the presence of blood
doping antibodies at some point, a horse with a trainer who has ever had
a horse test positive for EPO and any horse that dies or is euthanized on
association grounds for any reason.
Kentucky falls into the latter category; “any horse eligible to race in
Kentucky” is its guideline. Kentucky defines this as a horse being eligible if
the owner or trainer is licensed in that state, if it is nominated to a race in
that state or if it raced in Kentucky within the past 12 months, if it is stabled
at a racetrack or licensed training facility or if it is nominated to the Kentucky
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Thoroughbred Development Fund. Kentucky testing is supposed to be limited
to natural or synthetic types of blood doping substances, venoms and growth
hormones.
New Mexico is broader in what it tests for but slightly limited more to
horses in its area. The state may test horses on the grounds, horses with
papers that are on file, horses nominated to stakes or horses with an owner or
trainer licensed in the state. New Mexico also tests for clenbuterol and anabolic
steroids in addition to the Kentucky list. It also may test urine and hair, in
addition to blood. Illinois tests for blood and gene doping but specifically added
the following wording: “This Section does not apply to therapeutic medications
approved by the FDA for use in the horse.”
Gagliano, in his statement to the Thoroughbred Daily News, bemoaned the
fact that only 19 out of 38 states have out-of-competition testing. Perhaps the
states that are not currently doing this testing are waiting for a good rule to
follow. Racing commissions are woefully underfunded. Adopting a specific rule
just because it has the RMTC’s blessing does not mean it will stand up in a
court challenge. New York had an expensive, protracted legal fight on this issue,
the outcome being that the lawsuit was dropped when New York amended its
rule. The states that wait may be better off; they can create a fair and legally
validated rule, one that targets the cheaters and only the cheaters, and a rule
that will stand up when challenged in court.
All these states have a noble idea—get rid of the cheaters in the industry
and make it an even playing field for all horsemen. However, in the RMTC’s
quest to make the public think they are getting “tough on racing,” they actually
may be diluting the effectiveness of out-of-competition testing.
As it stands, California has the highest percentage of out-of-competition
testing, at 10 percent of all drug testing. Contrast this to Kentucky, where

What happens if trace levels of a substance administered before
a 2-year-old or horses of racing age sale are found months later
after the horse has changed hands?

a generous estimate is 2 percent of all drug testing. The RMTC regulation
heralded by Gagliano expands out-of-competition testing to routine therapeutic
medications, rather than expanding the number of horses tested for EPO
analogues or providing funding to develop testing for designer drugs. In
support of its regulation, the RCI recently sent out a survey that asked whether
respondents were in favor of expanded testing. What RCI failed to define was
“expanded.” Rather than expanding testing for substances that might actually
damage the integrity of horse racing, the proposed regulation seeks to expand
out-of-competition testing to legitimate therapeutic medications. By expanding
this testing to legitimate therapeutic medications, the proposed rule gives
chemists something to report in their out-of-competition testing reports and
thereby justifies the out-of-competition testing process and the entire regulatory
process itself and as such points to the claimed efficacy of the rule. Financially,
this approach has only one result. There will be fewer horses tested.
During the 2013 University of Arizona Global Symposium on Racing and
Gaming, Alan Foreman, chair of the Thoroughbred Horsemen’s Association, said
out-of-competition testing is designed to detect the use of substances like
blood-doping agents and “emerging drugs” like peptide venoms that can have
pain-killing effects. Testing for these illicit substances is “more important than
testing for 24 therapeutic drugs. Those aren’t the drugs compromising racing.”

CONCLUSION

As Gagliano suggests, the expansion of out-of-competition testing is a
goal worthy of widespread industry support. However, the details of the current
RMTC proposal, supported by The Jockey Club, fall short of actually improving
the integrity of horse racing. There are currently more than 80 EPO analogues,
and technology is only capable of identifying a handful. Designer anabolic
steroids and peptides can only be detected in limited numbers, because the
technology for finding anything is only now being developed. There is a need
for expanded out-of-competition testing and more widespread adoption of the
current regulations by racing jurisdictions but not for expanding this testing
into the administration of legitimate therapeutic medications. The proposed
regulation only criminalizes legal activity without providing even the tiniest
of steps toward addressing the true threats to the integrity of horse racing. In
the meantime, horsemen and vets have to waste precious resources and time
fighting the implementation of overly broadly drafted rules when our efforts,
one and all, would be better spent focusing as a united industry on ways to
identify true cheating. The mission of The Jockey Club would be better served
if its executives would emerge from their offices in the shade of the oak trees
and walk the backsides of our racetracks talking to the actual people who keep
them in their jobs.

UPDATE: NATIONAL HBPA WORKING HARD FOR POSITIVE CHANGE
Immediately following the Global Symposium on Racing and Gaming
in Tucson, Arizona, the Association of Racing Commissioners International
(RCI) scheduled meetings on December 8 and 9 at the Omni Resort, also in
Tucson. The National HBPA was present and represented by Dave Basler,
executive director of the Ohio HBPA, along with National HBPA President
and Chair Leroy Gessmann and CEO Eric Hamelback. The RCI Model Rules
Committee met first, followed by the RCI Board of Directors.
The RCI Model Rules Committee convened to discuss several topics.
One of those was the proposed changes submitted by the Racing Medication
and Testing Consortium (RMTC) to the current Multiple Medication Violation
(MMV) phase of the National Uniform Medication Program (NUMP).
Significant work went into reevaluating the current MMV phase by a
subcommittee of the RMTC, which was composed of a wide array of industry
stakeholders. Following the subcommittee’s changes and recommendations,
the RMTC board approved the amendments, which were then proposed in
writing to the RCI with the intention to amend the current model rule.
The changes that were amended to the MMV allowed for decreases
in the amount of time that points remain on a trainer’s record as well
as a decrease in the number of points assigned for medications that are
not performance-enhancing. More importantly, the changes would allow
stewards to have discretion in how many—if any—points are awarded
in cases where a positive test is the result of contamination and proven
through mitigating circumstances.
The significant progress made to improve the MMV component of the
NUMP now allows for support given to this phase by the NHBPA.
The changes were supported by a wide range of industry participants,
including the NHBPA and RMTC. The only opponent of the changes was The
Jockey Club.
“With the sensitivity of today’s testing, trainers are at a constant risk
of having a positive test from a miniscule amount of a substance a horse

might have ingested through contaminated feed, hay or other environmental
factors or through human contact,” said Hamelback. “Furthermore, these
positives are sometimes called at levels and for medications that could not
possibly affect performance on the track, so this is certainly a step in the
right direction. We thank the RCI, RMTC and all the other industry groups
who came together to improve the MMV and make it a fair system for all.”
Another topic discussed by the RCI Model Rules committee was the
proposed model rule discussed in this article to allow for out-of-competition
testing. While the NHBPA has been on the record supporting out-ofcompetition testing, it was important to note horsemen’s concerns related to
the drafted proposed model rule. The intention of the NHBPA’s presence at
the meeting was to state the organization’s opposition to the current content
and to express apprehension regarding the overreaching intent, which would
cause concern for horsemen’s rights.
Working together with Alan Foreman of the Thoroughbred Horsemen’s
Association, the NHBPA was successful in presenting opposition to the
original proposed model rule and thus initiating significant changes. While
concerns can still be voiced, the changes initiated by the Model Rules
Committee were very much in the favor of horsemen’s rights. Of particular
importance was the change made to the new out-of-competition testing
draft going before the RCI full board that involved the exclusion of results
found regarding therapeutic medications as non-relevant findings.
The NHBPA believes the progress made in the past few months has
been very encouraging. While it is important to say that we are working
together with many other stakeholders to initiate uniformity, it is also very
important to note that the voices and concerns identified for many years by
the NHBPA are finally getting proper recognition and orchestrating positive
change for our industry.
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